NCT04701476 2024-11-22
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Teclison Ltd.
Phase 2 Recruiting
Clinical Trials
5 trialsNCT02795156 2023-12-05
Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
SCRI Development Innovations, LLC
Phase 2 Completed
NCT03520842 2023-08-01
Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer
Stanford University
Phase 2 Completed
NCT05582031 2023-06-07
REFIT-MSS
Translational Research in Oncology
Phase 2 Withdrawn
NCT02307500 2022-09-10
RESOUND
Istituto Clinico Humanitas
Phase 2 Completed